Kenneth S. Koblan

2010

In 2010, Kenneth S. Koblan earned a total compensation of $1.7M as Chief Scientific Officer at Alnylam Pharmaceuticals.

Compensation breakdown

Non-Equity Incentive Plan$19,510
Option Awards$1,263,453
Salary$248,049
Other$212,394
Total$1,743,406

Koblan received $1.3M in option awards, accounting for 72% of the total pay in 2010.

Koblan also received $19.5K in non-equity incentive plan, $248K in salary and $212.4K in other compensation.

Rankings

In 2010, Kenneth S. Koblan's compensation ranked 3,481st out of 10,439 executives tracked by ExecPay. In other words, Koblan earned more than 66.7% of executives.

ClassificationRankingPercentile
All
3,481
out of 10,439
67th
Division
Manufacturing
1,210
out of 3,838
69th
Major group
Chemicals And Allied Products
236
out of 926
75th
Industry group
Drugs
130
out of 685
81st
Industry
Pharmaceutical Preparations
98
out of 481
80th
Source: SEC filing on May 2, 2011.

Koblan's colleagues

We found five more compensation records of executives who worked with Kenneth S. Koblan at Alnylam Pharmaceuticals in 2010.

2010

Laurence Reid

Alnylam Pharmaceuticals

Senior Vice President and Chief Business Officer

2010

John Maraganore

Alnylam Pharmaceuticals

Chief Executive Officer

2010

Barry Greene

Alnylam Pharmaceuticals

Chief Operating Officer

2010

Akshay Vaishnaw

Alnylam Pharmaceuticals

Senior Vice President, Clinical Research

2010

Patricia Allen

Alnylam Pharmaceuticals

Vice President of Finance and Treasurer

In-depth

You may also like